Q1 Earnings Forecast for ENTA Issued By HC Wainwright

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Enanta Pharmaceuticals in a research note issued on Tuesday, November 18th. HC Wainwright analyst B. Folkes anticipates that the biotechnology company will post earnings per share of ($0.53) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($2.56) EPS, FY2028 earnings at ($3.27) EPS and FY2029 earnings at ($2.48) EPS.

ENTA has been the subject of several other reports. Westpark Capital upped their target price on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective on the stock. Finally, JMP Securities boosted their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 12th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA opened at $12.73 on Friday. The firm has a 50-day simple moving average of $10.61 and a two-hundred day simple moving average of $8.46. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $15.34. The company has a market cap of $272.14 million, a P/E ratio of -2.95 and a beta of 0.88.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The firm had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ENTA. Farther Finance Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 5,779 shares during the last quarter. US Bancorp DE purchased a new position in shares of Enanta Pharmaceuticals in the 1st quarter valued at approximately $36,000. Quarry LP acquired a new stake in Enanta Pharmaceuticals in the 3rd quarter worth approximately $81,000. China Universal Asset Management Co. Ltd. boosted its stake in Enanta Pharmaceuticals by 103.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 4,454 shares in the last quarter. Finally, AlphaQuest LLC grew its position in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 1,562 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.